Clinical trial
Secukinumab Open Label Roll-over Extension Protocol
NCT04638647 · Novartis Pharmaceuticals, Industry · Recruiting
Key facts
| NCT number | NCT04638647 |
|---|---|
| Title | Secukinumab Open Label Roll-over Extension Protocol |
| Official title | An Open-label, Multi-center Protocol for Patients Who Have Completed a Previous Novartis Sponsored Secukinumab Study and Are Judged by the Investigator to Benefit From Continued Secukinumab Treatment |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Recruiting |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Autoimmunity, Inflammation |
| Intervention type | Biological |
| Interventions | Secukinumab s.c. injection |
| Enrollment | 1,000 |
| Start date | Dec 22, 2020 |
| Primary completion | Jan 29, 2030 |
| Completion | Apr 4, 2030 |
| First posted | Nov 20, 2020 |
| Last update posted | Dec 22, 2025 |
| Countries | Brazil, Bulgaria, China, Colombia, Czechia, Greece, Guatemala, India, Italy, Malaysia, Mexico, Poland and 7 more |
At a glance
- 100–999 Study sites
- No Results posted
- 10–99 FDA inspections linked to this trial
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: